Key result
Antisense oligonucleotides targeting SARS-CoV-2 and ACE2 potently block viral infection in vitro.
Why the study?
There remains a critical need for development of novel therapeutics against SARS-CoV-2, and antisense oligonucleotides have been relatively unexplored in COVID-19 treatment.
Do antisense oligonucleotides targeting the SARS-CoV-2 genome and host entry factors inhibit cellular infection in vitro?
Do antisense oligonucleotides targeting the SARS-CoV-2 genome and host entry factors inhibit cellular infection in vitro?
Antisense oligonucleotides targeting the SARS-CoV-2 genome and ACE2 demonstrate potent in vitro inhibition of viral infection, suggesting potential as COVID-19 therapeutics.
Answers are grounded in this paper and cite their sources.
ASO strategy for SARS-CoV-2 remains exploratory; leaves open whether targeted oligonucleotides can advance to clinical testing.
Although the COVID-19 pandemic began over three years ago, the virus responsible for the disease, SARS-CoV-2, continues to infect people across the globe. As such, there remains a critical need for development of novel therapeutics against SARS-CoV-2. One technology that has remained relatively unexplored in COVID-19 is the use of antisense oligonucleotides (ASOs)-short single-stranded nucleic acids that bind to target RNA transcripts to modulate their expression. In this study, ASOs targeted against the SARS-CoV-2 genome and host entry factors, ACE2 and TMPRSS2, were designed and tested for their ability to inhibit cellular infection by SARS-CoV-2. Using our previously developed SARS-CoV-2 bioassay platform, we screened 180 total ASOs targeting various regions of the SARS-CoV-2 genome and validated several ASOs that potently blocked SARS-CoV-2 infection in vitro. Notably, select ASOs retained activity against both the WA1 and B.1.1.7 (commonly known as alpha) variants. Screening of ACE2 and TMPRSS2 ASOs showed that targeting of ACE2 also potently prevented infection by the WA1 and B.1.1.7 SARS-CoV-2 viruses in the tested cell lines. Combined with the demonstrated success of ASOs in other disease indications, these results support further research into the development of ASOs targeting SARS-CoV-2 and host entry factors as potential COVID-19 therapeutics.
No takes yet. Share an insight, caveat, or question.
Qiao et al. (2023) studied SARS-CoV-2 infection. Antisense oligonucleotides (ASOs) targeting SARS-CoV-2 genome, ACE2, and TMPRSS2 was evaluated on Inhibition of cellular infection by SARS-CoV-2 in vitro. Antisense oligonucleotides targeting the SARS-CoV-2 genome and host entry factor ACE2 potently blocked cellular infection by WA1 and B.1.1.7 variants in vitro.
Synapse has enriched 10 related papers. Consider them for comparative context: